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OBJECTIVES: Hemophilia B is a rare and expensive to treat disease. The aim of this
studywas to develop an economic evaluation of prophylactic vs on-demand supply
of recombinant factor IX (rFIX) in the treatment of patients with severe hemophilia
B, from the Social Security Mexican Institute (IMSS) perspective. METHODS: A
three-state Markovmodel (two-week cycles) followingmale patients from birth up
to 75 years was developed to estimate the cost and outcomes of prophylactic (30
IU/kg body weight/week) and on-demand (40 IU/kg body weight/joint bleed) ap-
proaches to manage haemophilia B. On-demand was considered the usual prac-
tice. Effectiveness measure was the QALY. A literature review was performed to
extract Mexican demographic and general epidemiologic data needed to populate
the model. Treatment cost data (inpatient, outpatient, emergency services, medi-
cines, laboratory and image studies) were extracted fromMexican published data-
bases (the acquisition cost of rFIX was provided by the manufacturer). Health and
economic consequences were assessed in different age groups. Both costs and
outcomes were discounted at 5% annual rate Probabilistic sensitivity analyses and
acceptability curves were constructed. RESULTS: Cost of rFIX in prophylaxis rep-
resented 60.3% and 90.4% of the total annual cost in the 4 years and 19 years
groups, respectively. In on-demand approach, the cost of the therapy represented
45.3% and 83.9% in the4 years and19 years group, respectively. The incremen-
tal effectiveness for rFIX is close to one QALY in all age groups. The ICER of pro-
phylaxis in patients 4, 5-9, 10-14, 15-19, 19 years old was US$5,281.33,
US$14,586, US$15,172, US$20,398 and US$40,291/QALY gained, respectively. Ac-
ceptability curves showed an inverse relationship between age and cost-effective
proportion.CONCLUSIONS:At IMSS setting, the prophylaxiswith rFIX for theman-
agement of patients suffering severe hemophilia B appears to be a highly cost-
effective and a cost-effective intervention in children and teenagers, respectively.
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OBJECTIVES: Migraine is a common central nervous system disorder. The burden
of migraine is substantial due to its high prevalence and prominent temporary
disability. This study investigates the application of cost-effectiveness analysis,
from the Korean health care system perspective, for the comparison of eletriptan
40mg and sumatriptan 50mg in the acute treatment ofmigraine attack.METHODS:
A decision tree model was developed to estimate migraine treatment cost and
efficacy. Clinical data was derived from a clinical trial comparing oral eletriptan to
oral sumatriptan (G. Sandrini, 2002). Efficacy measures consisted of “pain-free at 2
hours (PF2)” and “sustained pain free for 2-24 hours (SPF)”. Drug costs for initial
dosing, second dosing for relapse, physician visit cost, and emergency visit cost
were taken into account. Citing 2008 HIRA report, physician visit cost and emer-
gency visit cost were calculated. All costs converted into 2011 Korean Won (KRW).
The time horizonwas a singlemigraine attack. RESULTS: In the base-case analysis,
assuming the eletriptan 40mg drug cost (4,775 KRW) is 20% higher than su-
matriptan 50mg drug cost (3,979 KRW), the average cost-effectiveness ratio (ACER)
were 23,702 KRW and 36,239 KRW (per attack at which PF2 is achieved) for
eletriptan 40mg and sumatriptan 50mg, respectively. Also, ACER for SPF per attack
is achieved was 26,054 KRW and 40,837 KRW for eletriptan 40mg and sumatriptan
50mg, respectively. CONCLUSIONS: Although eletriptan 40mg is more costly than
sumatriptan 50mg, because of eletriptan 40mg’s superior efficacy, the ACER of
eletriptan 40mg was lower than sumatriptan 50mg in the treatment of migraine
attack, with respect to PF2 and SPF aspects. Eletriptan 40mg has a potentially im-
portant role to play in the cost-effective management of migraine.
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OBJECTIVES: Pain management is an important dimension of postsurgical care.
The aim of this study was to determine the cost-effectiveness of parecoxib, mor-
phine, buprenorphine and ketorolac in themanagement of postsurgical pain, from
the perspective of the Mexican Social Security Institute (IMSS).METHODS: A deci-
sion-tree model was used to assess the outcomes of parecoxib 40mg; buprenor-
phine 0.12, 0.18 and 0.36mg;morphine 4, 6 and 12mg and ketorolac 30mg inwomen
who received them in the morning after their gynecologic surgery. In case of fail-
ure, rescue therapy with morphine 4mg was allowed. The time horizon is 12 hours
after the medication was received. Only the acquisition cost was considered (2011
US$). The effectiveness outcome was the proportion of respondents who experi-
enced onset of analgesia and rated their medication as “good” or “excellent”
(through patient=s global evaluation of the study medication questionnaire). Liter-
ature reviewwas performed to extract the clinical outcomes of competing alterna-
tives (the doses of morphine 4mg, buprenorphine 0.12mg and so on, were consid-
ered equianalgesic). Acquisition costs were extracted from official institutional
sources. The results of the analysis are expressed through the ICER (ketorolac as
basecase). Univariate sensitivity analysis was performed. RESULTS: The propor-
tion of respondents treated withmorphine 4mg-buprenorphine 0.12mg, morphine
6mg-buprenorphine 0.18mg, morphine 12mg-buprenorphine 0.36mg, ketorolac
and parecoxib was 44.21%; 44.21%; 46.42%; 63.64% and 71.76%, respectively. The
expected cost per patient ofmorphine 4mg, buprenorphine 0.12mg,morphine 6mg,
buprenorphine 0.18mg, morphine 12mg, buprenorphine 0.36mg, ketorolac and
parecoxib was $4.53; $1.45; $6.32; $1.71; $11.69; $2.48; $0.84 and $7.12, respectively.
All the alternatives (except parecoxib, ICER: $77.30) are dominated by ketorolac.
Furthermore, parecoxib ismore effective than competing alternatives but only less
expensive than morphine 12mg. CONCLUSIONS: At IMSS setting, parecoxib ap-
pears to be cost-saving regarding morphine 12mg and cost-effective regarding ke-
torolac, buprenorphine and morphine 4 and 6mg.
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OBJECTIVES: Based on an economic evaluation of cost-effectiveness of frontline
dasatinib treatment for chronic myeloid leukemia by the York Consortium and
after transferability analysis of data, we performed an adaptation of this model in
Colombia and Venezuela. We compared the costs and cost-effectiveness ratio of
dasatinib 100 mg/day versus imatinib 400 mg/day and nilotinib 600 mg/day as
frontline treatment for CML in its three phases. with increases to 140 mg/day of
dasatinib, 800 mg/day of imatinib and 800 mg/day nilotinib in a second-line
therapy. METHODS: The original model considered those patients with CML who
had not received previous treatment and a Markov=s model with probabilities of
change for the chronic, accelerated and death phases, over the lifetime and with a
costs and benefits discount rates of 3.5%. Direct medical and treatment cost and
mortality rates were taken from the local jurisdiction and WHO life tables. The
results of the model included the costs of each alternative treatment with dasat-
inib, nilotinib or imatinib and the QALYs (Quality Adjusted Life Years). Costs are
expressed in 2011 Colombian pesos and Venezuelan strong bolivars. RESULTS:
Dasatinib 100 mg/day as frontline treatment for CML produced the greatest num-
ber of QALYs, both in Colombia and Venezuela with 10.67 and 10.53 QALYs respec-
tively, comparedwith imatinib; 10.10 and 9.97 QALYs and nilotinib; 10.50 and 10.36
QALYs Dasatinib 100 mg/day was also more cost-effective than nilotinib as front-
line treatment for CML, being dominant in both these countries. CONCLUSIONS: In
the frontline treatment for CML in Colombia and Venezuela, Dasatinib was more
effective than imatinib and nilotinb and showed better rates of cost-effective than
nilotinib been dominant in both countries. Although there was an increase in over-
all costs, this is due to the increase in life years gained and thus in greater use of
medical resources and medications.
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OBJECTIVES: Metabolic Syndrome (MetS) is defined as a clustering of risk factors
for diabetes mellitus (T2DM) and cardiovascular disease (CVD) which puts individ-
uals at increased risk of developing these conditions and consequently leads to a
reduction in life expectancy and increased morbidity. METHODS: A systematic
review and network meta-analysis was undertaken to assess the relative clinical
effectiveness of a number of lifestyle and pharmacological interventions, both
independently and in combination. A second systematic review, and series of
meta-analyses, was also undertaken to estimate the increased burden that a MetS
diagnosis has on the subsequent risk of T2DM, CVD and all-causemortality. A fully
probabilistic economic Markov decision model was developed in WinBUGS, and
which directly included the series of meta-analyses above, in order to assess the
cost-effectiveness of the various interventions. RESULTS: The use of both lifestyle
and pharmacological interventions in combination was dominated in the incre-
mental cost-effectiveness analysis, with the use of both of them independently
producing greater health gain at lower cost. Pharmacological intervention was
cost-effective compared to standard care (ICER £3050 with a probability of 0.53 at a
threshold value of £20K/QALY), and lifestyle intervention was cost-effective com-
pared to pharmacological (ICER £6933with a probability of 0.52 at a threshold value
of £20K/QALY). A series of sensitivity analyses were also undertaken both with
regards to the model inputs/distributions and a number of methodological as-
sumptions, but the results remained largely insensitive to these changes.
CONCLUSIONS: The use of a lifestyle intervention would appear to be a potentially
cost-effective treatment strategy for adults with MetS, however considerable un-
certainty surrounds this decision. The use of a comprehensive approach to eco-
nomic modelling within a WinBUGS framework allowed distributional assump-
tions to be relaxed, sources of correlation to be appropriately accounted for, and
more complex sensitivity analyses to be easily undertaken.
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OBJECTIVES: To assess the cost-effectiveness of lenalidomide with dexametha-
sone (Len/Dex) combination relative to bortezomib alone, in previously treated
multiple myeloma patients in Greece. METHODS: A discrete event simulation
model was locally adapted, to estimate the differences in the overall survival and
treatment cost for the two alternative options. Efficacy data utilized came from the
two large,multicenter, controlled, randomized clinical trials for the first option and
an open label study for the second. Quality of life data were extracted from inter-
national sources. Data on resource use and prices were collected from the elec-
tronic databases of local hospitals and other relevant sources. The perspective of
the analysis was that of payers. Total cost accounts for themonitoring and admin-
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